Cancer Immunotherapy Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 137.71 Billion |
| Market Size (2029) | USD 226.34 Billion |
| CAGR (2024 - 2029) | 10.45 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cancer Immunotherapy Market Analysis
The Cancer Immunotherapy Market size is estimated at USD 137.71 billion in 2024, and is expected to reach USD 226.34 billion by 2029, growing at a CAGR of 10.45% during the forecast period (2024-2029).
- The cancer immunotherapy market is undergoing a significant transformation, primarily driven by the escalating prevalence of cancer and the increasing adoption of innovative therapies. Immunotherapy, which amplifies the body's immune system to combat cancer, has gained substantial attention due to its effectiveness compared to traditional treatments like chemotherapy and radiation. This market is characterized by advancements in monoclonal antibodies , cancer vaccines, immunomodulators, and immune checkpoint inhibitors. These therapies are increasingly favored for their precision in targeting cancer cells, thereby enhancing patient outcomes.
Expanding R&D Efforts in Immunotherapy
- The surge in research and development (R&D) activities is playing a critical role in the cancer immunotherapy market. Ongoing research is driving the creation of more advanced and targeted therapies, with the aim of increasing the efficacy and safety of cancer treatments. The emphasis on personalized medicine, which customizes treatment to individual genetic profiles, is a significant driver of these R&D efforts. This approach not only improves therapeutic outcomes but also minimizes adverse effects, making treatments more patient-centric.
- Innovations and Pipeline Developments: Pharmaceutical companies are heavily investing in the R&D of novel immunotherapies, with numerous drugs in the pipeline showing promising results in early clinical trials. Innovations such as next-generation monoclonal antibodies, bi-specific antibodies, and T-cell therapies are expected to provide more effective solutions against various cancer types. This ongoing research is crucial for addressing the complexities of cancer treatment, aiming for higher remission rates and prolonged survival periods.
- Collaborative Research Initiatives: Collaborative efforts among academic institutions, research organizations, and pharmaceutical companies are accelerating discoveries in the immunotherapy field. These partnerships facilitate knowledge and resource sharing, leading to the development of cutting-edge treatments and expanding the therapeutic options available to cancer patients worldwide. Such collaborations are essential for overcoming challenges in drug development, including regulatory hurdles and high costs.
Advancements in Therapy Effectiveness and Precision
- The increasing effectiveness and precision of new therapies are reshaping the cancer immunotherapy market. These advancements allow for treatments that are more specific to cancer cells, minimizing damage to healthy cells and reducing side effects, thereby enhancing the overall patient experience and outcomes.
- Precision Medicine: Precision medicine has revolutionized cancer treatment, enabling therapies to be tailored to the genetic makeup of individual tumors. This personalized approach increases the efficacy of immunotherapies by targeting specific mutations within cancer cells, leading to more successful treatment outcomes. The development of immune checkpoint inhibitors, which have shown significant success in treating cancers with high mutational burdens, exemplifies this trend.
- Enhanced Therapeutic Accuracy: Innovations such as CAR-T cell therapy and bi-specific T-cell engagers (BiTEs) are at the forefront of increasing therapeutic accuracy. These therapies are engineered to recognize and attack specific cancer antigens, offering a highly targeted treatment approach. This precision not only improves the effectiveness of cancer treatment but also reduces the likelihood of recurrence, offering a significant advantage over conventional therapies.
Cancer Immunotherapy Market Trends
Breast Cancer Segment Expected to Hold a Major Share in the Cancer Immunotherapy Market
- The breast cancer segment is anticipated to dominate the cancer immunotherapy market due to the rising global incidence of breast cancer. This disease remains the most common cancer among women, driving the demand for innovative and effective treatment options. As breast cancer cases continue to increase, the need for targeted therapies, such as immunotherapy, becomes critical for improving patient outcomes and reducing recurrence rates. This trend underscores the growing significance of the breast cancer segment within the overall cancer immunotherapy market.
- Advancements in Breast Cancer Immunotherapy: Rapid advancements in cancer immunotherapy, such as checkpoint inhibitors, monoclonal antibodies, and CAR T-cell therapies, have revolutionized breast cancer treatment. These therapies provide more personalized and effective options compared to traditional methods. Ongoing research and development are expected to further enhance the efficacy of these treatments, solidifying the breast cancer segment's dominant position in the cancer immunotherapy market. The focus on personalized medicine, tailored to individual genetic profiles, is likely to boost market growth.
- Market Growth Driven by Awareness and Research: Increased awareness and research initiatives are key drivers of the breast cancer segment's growth within the cancer immunotherapy market. Organizations like the Breast Cancer Research Foundation (BCRF) and breastcancer.org play a crucial role in funding research and providing up-to-date information, which fuels advances in treatment options. This growing awareness, coupled with continuous research and development, is expected to sustain the segment's significant share of the global cancer immunotherapy market.
North America Expected to Continue Market Dominance over the Forecast Period
- North America's dominance in the cancer immunotherapy market is largely attributed to its advanced healthcare infrastructure. The region's well-established healthcare systems, particularly in the United States and Canada, facilitate the rapid adoption of cutting-edge therapies. This infrastructure ensures timely access to innovative treatments, positioning North America as a leader in the global cancer immunotherapy market. The region's robust healthcare framework is a key factor in maintaining its market leadership over the forecast period.
- Government Initiatives and Market Growth: Government initiatives in North America, including favorable reimbursement policies and substantial funding for cancer research, are driving market growth. These initiatives have been pivotal in creating a conducive environment for the development and commercialization of new cancer immunotherapy treatments. The U.S. government's commitment to cancer research, exemplified by initiatives like the Cancer Moonshot, highlights the region's focus on innovation and market expansion in this sector.
- Increasing Cancer Burden and Market Potential: The rising incidence of cancer in North America, particularly in the United States, presents significant market potential for cancer immunotherapy. According to GLOBOCAN, the U.S. alone saw over 2.2 million new cancer cases in 2020, with lung cancer being particularly prevalent in Canada. This increasing cancer burden underscores the urgent need for effective treatments, which, in turn, propels the demand for immunotherapies. As market players continue to launch new products and awareness grows, the cancer immunotherapy market in North America is poised for lucrative growth in the coming years.
Cancer Immunotherapy Industry Overview
- The cancer immunotherapy market is moderately consolidated, with a mix of global pharmaceutical giants and specialized biotechnology firms dominating the landscape. Major players include a combination of diversified pharmaceutical companies and firms dedicated to oncology treatments. These companies have established themselves through innovative immunotherapy treatments, extensive research and development pipelines, and strategic partnerships. The market is characterized by ongoing competition among these key players, making it challenging for smaller or newer companies to gain significant market share without innovative approaches.
- Market Leaders Driving Innovation and Growth: The primary market leaders—Amgen Inc., Astellas Pharma, Inc., AstraZeneca PLC, Merck & Co. Inc., and OSE Immunotherapeutics—are known for their strong focus on developing novel cancer immunotherapy solutions. These companies have built extensive portfolios that include monoclonal antibodies, checkpoint inhibitors, and cancer vaccines, among other therapies. Their robust R&D investments, coupled with strategic acquisitions and collaborations, enable them to maintain a competitive edge. Additionally, their global reach and strong distribution networks further solidify their positions in the market.
- Future Success Dependent on Continued Innovation and Strategic Alliances: Several trends are shaping the cancer immunotherapy market, including the increasing adoption of personalized medicine and the integration of advanced technologies such as artificial intelligence in drug discovery. For companies to succeed, they must continue to innovate, focusing on developing next-generation immunotherapies that target a broader range of cancers. Strategic alliances, both with biotech firms and academic institutions, are essential for staying ahead in this competitive market. Companies that can effectively leverage these strategies while navigating regulatory challenges will likely dominate the market in the coming years.
Cancer Immunotherapy Market Leaders
-
Amgen Inc.
-
Astellas Pharma, Inc.
-
AstraZeneca PLC
-
Merck and Co Inc.
-
OSE Immunotherapeutics
*Disclaimer: Major Players sorted in no particular order
Cancer Immunotherapy Market News
- In August 2024, AstraZeneca’s Imfinzi (durvalumab), an immunotherapy in combination with chemotherapy was approved in the United States for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
- In June 2024, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck), a type of immunotherapy that can be used with carboplatin and paclitaxel. This combination is followed by a regimen of single-agent pembrolizumab, specifically targeting adult patients suffering from primary advanced or recurrent endometrial carcinoma.
Cancer Immunotherapy Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising R&D Activities
- 4.2.2 Increasing Effectivity and Accuracy Of Newer Therapies
- 4.2.3 Growing Prevalence of Cancer
-
4.3 Market Restraints
- 4.3.1 High Cost Coupled with Expensive Development
- 4.3.2 Stringent Regulatory Factors
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Therapy Type
- 5.1.1 Monoclonal Antibodies
- 5.1.2 Cancer Vaccines
- 5.1.3 Immunomodulators
- 5.1.4 Immune Check Point Inhibitors
- 5.1.5 Other Therapy Types
-
5.2 By Application
- 5.2.1 Prostate Cancer
- 5.2.2 Breast Cancer
- 5.2.3 Skin Cancer
- 5.2.4 Lung Cancer
- 5.2.5 Other Applications
-
5.3 By End Users
- 5.3.1 Hospitals and Clinics
- 5.3.2 Cancer Research Centers
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Amgen Inc.
- 6.1.2 Astellas Pharma Inc.
- 6.1.3 AstraZeneca PLC
- 6.1.4 Bayer AG
- 6.1.5 Bristol-Myers Squibb
- 6.1.6 Eli Lilly and Company
- 6.1.7 F. Hoffman La Roche Ltd
- 6.1.8 Merck and Co. Inc.
- 6.1.9 Novartis AG
- 6.1.10 OSE Immunotherapeutics
- 6.1.11 Seattle Genetics Inc.
- 6.1.12 Pfizer Inc.
- 6.1.13 Gilead Sciences
- 6.1.14 GSK PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCancer Immunotherapy Industry Segmentation
As per the scope of the report, immunotherapy is a treatment that uses certain parts of a person's immune system to fight diseases, such as cancer. This can be done either by stimulating one's own immune system to work better to attack cancer cells or by giving one immune system components, such as artificial immune system proteins. Cancer immunotherapy boosts the body's natural defenses to fight against cancer. It uses substances made by the body or in a laboratory to improve the immune system to find and destroy cancer cells.
The cancer immunotherapy market is segmented by therapy type, application, end users, and geography. By therapy type, the market is segmented into monoclonal antibodies, cancer vaccines, immunomodulators, immune checkpoint inhibitors, and other therapy types. By application, the market is segmented into prostate cancer, breast cancer, skin cancer, lung cancer, and other applications. By end users, the market is segmented into hospitals and clinics, cancer research centers, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD ) for the above segments.
| By Therapy Type | Monoclonal Antibodies | |
| Cancer Vaccines | ||
| Immunomodulators | ||
| Immune Check Point Inhibitors | ||
| Other Therapy Types | ||
| By Application | Prostate Cancer | |
| Breast Cancer | ||
| Skin Cancer | ||
| Lung Cancer | ||
| Other Applications | ||
| By End Users | Hospitals and Clinics | |
| Cancer Research Centers | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Cancer Immunotherapy Market Research FAQs
How big is the Cancer Immunotherapy Market?
The Cancer Immunotherapy Market size is expected to reach USD 137.71 billion in 2024 and grow at a CAGR of 10.45% to reach USD 226.34 billion by 2029.
What is the current Cancer Immunotherapy Market size?
In 2024, the Cancer Immunotherapy Market size is expected to reach USD 137.71 billion.
Who are the key players in Cancer Immunotherapy Market?
Amgen Inc., Astellas Pharma, Inc., AstraZeneca PLC, Merck and Co Inc. and OSE Immunotherapeutics are the major companies operating in the Cancer Immunotherapy Market.
Which is the fastest growing region in Cancer Immunotherapy Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cancer Immunotherapy Market?
In 2024, the North America accounts for the largest market share in Cancer Immunotherapy Market.
What years does this Cancer Immunotherapy Market cover, and what was the market size in 2023?
In 2023, the Cancer Immunotherapy Market size was estimated at USD 123.32 billion. The report covers the Cancer Immunotherapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Cancer Immunotherapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cancer Immunotherapy Industry Report
Our industry research in the cancer immunotherapy market delves into the rapidly evolving landscape shaped by innovative treatments and increasing cancer prevalence. The report offers a comprehensive industry overview, highlighting critical advancements such as monoclonal antibodies, cancer vaccines, and immune checkpoint inhibitors. Stakeholders benefit from our detailed market segmentation, which includes therapy types, applications across various cancer types, and geographical analysis. The report also covers the latest trends in personalized medicine and precision therapies, providing actionable insights that are crucial for strategic decision-making in this dynamic market. All findings and data are presented in an easy-to-read report pdf, ensuring accessibility for all users.
In this industry report, we meticulously analyze the competitive landscape, emphasizing the role of leading pharmaceutical companies and the impact of their ongoing research and development efforts. Our market forecast includes projections for growth driven by increasing R&D activities and strategic collaborations. This report pdf serves as an essential resource for understanding the complexities of the cancer immunotherapy market, offering valuable information that helps businesses stay ahead of industry trends and capitalize on emerging opportunities.
Statistics for the 2024 Cancer Immunotherapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cancer Immunotherapy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
